Market News
Global Myeloproliferative Neoplasms Treatment Market: Key Developments
- On June 10, 2022, AbbVie, a pharmaceutical company headquartered in Illinois, U.S., announced new data from its phase 2 study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF). These preliminary findings show spleen volume and symptomatic improvement in this cohort.
- On May 26, 2022, Protagonist Therapeutics, a clinical stage biopharmaceutical company, announced new data from its ongoing phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera (PV). It was presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from June 3, 2022.